Compare BridgeBio Pharma Inc (BBIO) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Kohl's Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.38 (market cap $16.36B), while Kohl's Corporation trades at $18.78 (market cap $2.10B). The key difference: BridgeBio Pharma Inc is far larger — about 7.8× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.7% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KSS | |
|---|---|---|
Market Cap | $16.36B | $2.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $24.71 |
52-Week Low | $47.29 | $11.72 |
Enterprise Value | $18.14B | $8.20B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
Kohl's stock trades at $19.04, down 1.35% with a bullish technical signal despite recent weakness. The company shows improving fundamentals with three consecutive earnings beats and positive cash flow projections for 2026. Valuation metrics appear attractive with P/E of 7.77 and P/B of 0.52, while recent management changes and proprietary brand growth provide operational momentum.
Kohl's presents a turnaround opportunity with undervalued metrics and improving operational execution, though declining revenue and thin margins pose significant challenges. Analyst consensus remains cautious with a $16.75 price target below current levels, reflecting concerns about sustained growth in a competitive retail environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
